Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tetrac (Tetraiodothyroacetic acid)是L-甲状腺素(T4)的衍生物,是一种甲状腺整合素受体拮抗剂。Tetrac通过阻断EGFR介导的结直肠癌细胞信号传导来诱导抗增殖。Tetrac 可阻断 T4 和 3,5,3'-triiodo-L-thyronine (T3)在细胞表面甲状腺素整合素 αvβ3 受体上的作用。Tetra 具有抗血管生成、抗肿瘤活性和促凋亡活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 257 | 现货 | ||
10 mg | ¥ 363 | 现货 | ||
25 mg | ¥ 589 | 现货 | ||
50 mg | ¥ 866 | 现货 | ||
100 mg | ¥ 1,290 | 现货 | ||
500 mg | ¥ 3,550 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 393 | 现货 |
产品描述 | Tetrac (Tetraiodothyroacetic acid) is a derivative of L-thyroxine (T4), a thyroxine integrin receptor antagonist.Tetrac induces antiproliferation by blocking EGFR-mediated cell signaling in colorectal cancer cells.Tetrac blocks the effects of T4 and 3,5,3'-triiodo-L-thyronine (T3) on the cell-surface thyroxine integrin αvβ3 receptors.Tetra has anti-angiogenic, anti-tumor activity and pro-apoptotic activity. |
体外活性 | Tetrac (0.01-1 μM; 2-6 d) induces anti-proliferation in HT-29 and HCT116 cells with different K-RAS status[3].Tetrac (0.1 μM; 30 min) inhibits activation of ERK1/2 in HT-29 and HCT116 cells[3].Tetrac (0.1 μM; 24 h) inhibits expression of CCND1 and c-Myc, but promotes expression of CASP2 and THBS1[3]. Cell Proliferation Assay[3] Cell Line: HT-29 and HCT116 cells |
体内活性 | Tetrac (35 μg/day; p.o.; for 40 days; Wild-type male Balb/C mice inoculated with 102B16F10 or B16LS9 cells) delayed the onset of ocular melanoma and reduced the S-100 and integrin staining levels. Tetrac can inhibit tumor inoculation, growth, and integrin expression in mice.[4] |
别名 | Tetraiodothyroacetic acid, 3,3',5,5'-Tetraiodothyroacetic acid |
分子量 | 747.83 |
分子式 | C14H8I4O4 |
CAS No. | 67-30-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 74.78 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.3372 mL | 6.686 mL | 13.372 mL | 33.4301 mL |
5 mM | 0.2674 mL | 1.3372 mL | 2.6744 mL | 6.686 mL | |
10 mM | 0.1337 mL | 0.6686 mL | 1.3372 mL | 3.343 mL | |
20 mM | 0.0669 mL | 0.3343 mL | 0.6686 mL | 1.6715 mL | |
50 mM | 0.0267 mL | 0.1337 mL | 0.2674 mL | 0.6686 mL | |
100 mM | 0.0134 mL | 0.0669 mL | 0.1337 mL | 0.3343 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tetrac 67-30-1 Angiogenesis Apoptosis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR Tetraiodothyroacetic acid 3,3',5,5'-Tetraiodothyroacetic acid Inhibitor inhibitor inhibit